Last checked at 17 Jan 2020 12:12
17 January 2020
Result of General Meeting, Issue of Equity, Admission and Total Voting Rights
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology and focused on sexual health and pain, announces that, at its General Meeting held earlier today, all resolutions were duly passed by the shareholders.
Application has been made to the London Stock Exchange for 40,625,000 Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will be effective and trading will commence at 8.00 a.m. on 20 January 2020.
Following Admission, the Company will have 245,285,267 Ordinary Shares in issue. As the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 245,285,267 and this figure may therefore be used by Shareholders.
Terms in this announcement have the meaning given to them in the Circular issued in connection with the Fundraising and the announcement released on 20 December 2019 with the RNS Number 7183X.
For further information please contact:
Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670www.Futuramedical.com
Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144